Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Paolo A. Ascierto | Researchclopedia

Back to researchers

Paolo A. Ascierto

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"ORCID

1,653

Works

108,684

Citations

126

h-index

662

i10-index

Research Topics

Cancer Immunotherapy and Biomarkers Melanoma and MAPK Pathways CAR-T cell therapy research

Affiliations

Université Paris-Sud2013–2013

Roche (Switzerland)2024–2024

Indiana University Health2005–2005

Novartis (Switzerland)2024–2024

The University of Sydney2023–2023

Top Works

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin,Vanna Chiarion‐Sileni,et al.

20158,060 citations

Cutaneous Melanoma Detection and Management

Immunotherapy and Immune Responses

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman,Axel Hauschild,et al.

20117,653 citations

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok,Vanna Chiarion‐Sileni,et al.

20175,339 citations

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert,Georgina V. Long,et al.

20145,316 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin,Vanna Chiarion‐Sileni,et al.

20193,648 citations

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurélien Marabelle,Dung T. Le,et al.

20192,876 citations

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber,Sandra P. D’Angelo,et al.

20152,651 citations

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey S. Weber,Mario Mandalà,et al.

20172,176 citations

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin,Paolo A. Ascierto,et al.

20142,016 citations